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Enterohemorrhagic Escherichia coli O157:H7 (EHEC O157:H7) causes hemorrhagic
colitis and the formation of characteristic attaching and effacing (A/E) lesions in humans.
Given the severe sequelae of EHEC O157:H7 infection, it is critical to develop effective
vaccines for human use. However, for achieving this goal many hurdles need to be
addressed, such as the type or subset of antigens, adjuvant, and the delivery route. We
developed a candidate vaccine by inserting the bivalent antigen espA-Tir-M composed
of espA and the Tir central domain into Lactobacillus acidophilus. The recombinant
L. acidophilus (LA-ET) was safe in a cell model and excluded EHEC O157:H7 from LoVo
cells at rates of nearly 94 and 60% in exclusion and competition assays, respectively.
LA-ET inhibited the induction of A/E lesions by EHEC O157:H7 cells in vitro. Oral
immunization with LA-ET induced higher levels of specific mucosal and systemic
antibody responses in mice. Moreover, LA-ET enhanced interferon-γ and interleukin-4
and -10 production, which was associated with mixed helper T (Th1/Th2) cell responses,
and protected against EHEC O157:H7 colonization and infection in mice at a rate of
80%. Histopathological analyses revealed that orally administered LA-ET reduced or
inhibited A/E lesions and toxin-induced systemic injury. These findings demonstrate that
LA-ET induces both humoral and cellular immune responses in mice and is therefore a
promising vaccine against EHEC O157:H7 infection.
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INTRODUCTION
Enterohemorrhagic Escherichia coli O157:H7 (EHEC O157:H7) is a zoonotic enteric pathogen that
causes hemorrhagic colitis and hemolytic uremic syndrome (HUS) in humans (Remis et al., 1984;
Armstrong et al., 1996). EHEC O157:H7 can intimately adhere to intestinal epithelial cells and form
characteristic attaching and effacing (A/E) lesions, and antibiotic treatment can potentially increase
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HUS risk (Besser et al., 2001; Wong et al., 2012). It is presumed
that a vaccine that prevents EHEC from colonizing the intestinal
tract would be the most effective strategy for preventing infection
(Mayr et al., 2005). Currently, two vaccines are used for the same
purpose in cattle, but neither has been approved for humans
(Larrie-Bagha et al., 2013). For achieving this goal many hurdles
need to be addressed, such as the type or subset of antigens,
adjuvant, and the delivery route.
The virulence of EHEC O157:H7 can be largely attributed to
its toxins, type III secretion system (T3SS) proteins, and surface
fimbrial and afimbrial adhesions (Garcia-Angulo et al., 2013).
The T3SS delivers espA, espB, and espD directly to the host
cells, which are essential for signal transduction and A/E lesion
formation (Frankel et al., 1998). The major component, espA
forms a bridge to host cells for direct delivery of other virulence
factors (Li et al., 2000). Tir is one of the first proteins translocated
during infection and functions as a receptor for the EHEC outer
membrane protein, intimin (DeVinney et al., 1999). The T3SS
proteins, espA and Tir thus play key roles in EHEC adhesion,
pedestal formation, and pathogenicity. They may also serve as
immunogens for the disruption of bacterial-host cell interaction
and prevent the formation of A/E lesions.
Lactic acid bacteria (LAB) such as Lactobacillus acidophilus
(L. acidophilus), Lactococcus lactis, and Bifidobacterium have
been given a “generally regarded as safe” (GRAS) designation
and are widely used in human food production. Additionally,
LAB’s are considered as a useful tool for the development of
novel oral vectors and have largely replaced attenuated pathogens
with mucosal delivery strategies (Bermudez-Humaran et al.,
2011). Moreover, LAB can also be used as delivery vectors for
subunit vaccines, which circumvents costly purification processes
(Wells, 2011). Vaccines employing a mucosal delivery system
can elicit both antigen-specific secretory immunoglobulin A
(sIgA) and effective systemic immune responses. The relatively
low cost, ease of administration, and degree of mucosal tissue
protection make LAB more advantageous as vaccine delivery
vectors (Rosales-Mendoza et al., 2016). Lactococcus lactis is
most often used for EHEC and other pathogen vaccines.
Lactococcus lactis-expressing EspB induces protective immunity
against EHEC O157:H7 and recombinant Lactococcus lactis
induces protection against C. difficile (Ahmed et al., 2014; Guo
et al., 2015). However, there are few reports describing the
use of L. acidophilus as a vaccine delivery vector that has
been approved for use in infant and baby food. L. acidophilus
is particularly promising as an oral vaccine vector because it
is acid- and bile-tolerant, can express mucus-binding proteins
that enable association with intestinal mucosa and regulates
immature dendritic and T cell functions (Konstantinov et al.,
2008). To date, there have been no studies of recombinant
L. acidophilus producing the EHEC O157:H7 protective antigen
as a candidate vaccine. In this study, we developed a
candidate EHEC O157:H7 vaccine by inserting the bivalent
antigen espA-Tir-M (ET), which is composed of espA and
the Tir central domain (Tir-M), into L. acidophilus. We
evaluated the specific immune responses elicited in mice and
protection against EHEC O157:H7 challenge both in vitro and
in vivo.
MATERIALS AND METHODS
Bacteria, Plasmids, and Cells
Lactobacillus acidophilus ATCC4356 (American Type Culture
Collection, Manassas, VA, USA) was cultured in de Man, Rogosa,
and Sharpe (MRS) agar or broth at 37◦C in an atmosphere of
5% CO2. EHEC O157:H7 strain EDL933 (our laboratory stock)
was grown at 37◦C in Luria–Bertani (LB) broth supplemented
with 5 g/l streptomycin. The pMG36e plasmid (our laboratory
stock) was maintained in DH5α cells and cultured in LB broth
with 200 µg/ml erythromycin, and pMG36e-based plasmids were
maintained in MRS agar or broth with 0.1 µg/ml erythromycin.
The LoVo human colonic cancer cell line (our laboratory stock)
was cultured in Roswell Park Memorial Institute (RPMI) 1640
medium containing 10% fetal bovine serum (FBS) at 37◦C in a
humidified atmosphere of 5% CO2.
Construction of Recombinant
L. acidophilus Strain
To construct the recombinant plasmid pMG36e-espA-Tir-M, the
espA-Tir-M (ET) fragment was amplified by overlap extension
PCR from espA (GenBank accession no. KJ549678.1) and Tir-M
(GenBank accession no. NC002655.2). EspA and Tir-M
fragments were joined with a linker (GGA GGC GGA AGT GGA
GGA GGT AGC). Both espA and Tir-M were PCR-amplified
from E. coli O157:H7 EDL933 using primer pairs with the
following sequences: P1 (forward), 5′-A AAA CTGCAG GAT
GGA TAC ATC AAA TGC A- 3′ and P2 (reverse), 5′-GCT ACC
TCC TCC ACT TCC GCC TCC TTT ACC AAG GGA TAT
TGC TG-3′ for espA; P3 (forward), 5′-GGA GGC GGA AGT
GGA GGA GGT AGC AGC CCA ACC ACG ACC GAC-3′ and
P4 (reverse), 5′-CCC AAGCTT TTA GGC TTG CTG TTT GGC
CTC TT-3′ for Tir-M; and P1/P4 for espA-Tir M. Restriction
enzyme sites (PstI and HindIII) are underlined. The fusion gene
espA-Tir-M was inserted into plasmid pMG36e.
The recombinant plasmid pMG36e-espA-Tir-M was trans-
formed into L. acidophilus cells according to the manufacturer’s
instructions for the expression system in Lactococcus lactis
(MoBiTec, Germany) with appropriate adjustment. Briefly, cells
were cultured in 4 ml of MRS broth with 0.05% cysteine-HCl
medium at 37◦C for 48 h. When the optical density at 600 nm
(OD600) reached 0.6, 4 ml of culture was diluted in 100 ml of MRS
broth with 0.5 M sucrose and 0.05% cysteine-HCl, followed by
incubation for approximately 24 h until the OD600 was 0.8. The
culture was cooled for 10 min and centrifuged at 5,000 rpm for
20 min at 4◦C, then washed twice in 20 ml of 0.5 M sucrose buffer.
The cells were re-suspended in 5 ml of pre-cooled transformation
buffer composed of 10 mM ammonium and 0.5 M sucrose
(pH = 6.0), then centrifuged at 5,000 rpm for 20 min at
4◦C and re-suspended in 400 µl of transformation buffer. The
recombinant plasmid was transformed into L. acidophilus cells
by electroporation using a Pulse Controller apparatus (Bio-Rad,
Hercules, CA, USA) at 2.5 kV and 25 µF. Transformed bacteria
were re-suspended in MRS broth and cultured at 37◦C for
1 h, and were plated on MRS agar (1.5%, w/v) with 0.1 µg/ml
erythromycin at 37◦C for 48 h. Positive colonies of transformed
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bacteria were identified by PCR-amplifying the target gene (espA-
Tir-M) and sequencing. The empty vector pMG36e transformed
into L. acidophilus cells (LA) served as a control.
Sodium Dodecyl Sulfate Polyacrylamide
Gel Electrophoresis (SDS-PAGE) and
Western Blot Analysis
The recombinant L. acidophilus (LA-ET) was cultured in MRS
broth with 0.1 µg/ml erythromycin at 37◦C for 24 h. The
supernatant was precipitated with trichloroacetic acid followed
by two washes with acetone. A 20 µl volume of sterile distilled
water was added to dissolve the supernatant proteins, which were
separated by 12% (w/v) sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and analyzed by western blotting
using an anti-EHEC O157:H7 polyclonal antibody (EterLife,
Birmingham, UK) according to the manufacturer’s instructions.
Cytotoxicity Analysis of LA-ET
LA-ET or LA at a multiplicity of infection (MOI) of 500:1 was
incubated with LoVo cells for 12 h, after which these cells were
harvested and washed with PBS. The cells were re-suspended in
500 µl of binding buffer containing 5 µl of FITC-Annexin V
and 5 µl of PI. The cells were gently vortexed and incubated for
15 min at room temperature in the dark. Finally, the cells were
detected using flow cytometry according to the manufacturer’s
instructions.
Inhibition of EHEC O157:H7 by Colonized
LoVo Cells
Inhibition of EHEC O157:H7 by LA-ET by the colonized LoVo
cells was evaluated using the following assays as previously
described (Satish Kumar et al., 2011). Briefly, 1 × 105 LoVo
cells per well were cultured in 24-well plates. For the exclusion
assay, the LoVo cells were pre-inoculated with LA-ET or
LA (MOI = 500:1) for 90 min and then, EHEC O157:H7
(MOI= 100:1) was added for co-incubation for 90 min at 37◦C.
For the competition assay, LA-ET or LA and EHEC O157:H7
were added to LoVo cells, followed by incubation at 37◦C for
3 h. LoVo cells inoculated with EHEC O157:H7 (MOI = 100:
1) for 90 min served as a positive control. To measure the
total number of adherent EHEC O157:H7 bacteria, cells were
lysed and the cell suspension was plated in triplicate on LB
agar and incubated for 24 h at 37◦C, after which the number
of colony-forming units (CFUs) was counted. Each experiment
was repeated three times. Results were calculated as a relative
adhesion percentage [100 × (number of adherent bacteria in the
experimental group)/(number of adherent bacteria in the positive
control group)].
LA-ET Inhibits EHEC O157:H7-Induced
Attaching and Effacing Lesions
Fluorescence actin staining (FAS) was performed to detect the
formation of A/E lesions. Briefly, LoVo cells were pre-incubated
with LA-ET (MOI = 500:1) for 3 h at 37◦C and then EHEC
O157:H7 (MOI = 100:1) cells were added for co-incubation for
3 h at 37◦C in 5% CO2. After incubation, cells were washed three
FIGURE 1 | Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and western blot analysis of proteins released by LA-ET
in the supernatant. (A) SDS-PAGE of LA-ET; M represents the molecular
size marker in kDa (Bio-Rad); Lane 1, supernatant of LA lysate; Lane 2,
supernatant of LA-ET lysate; Lane 3, culture supernatant of LA; Lane 4,
culture supernatant of LA-ET; (B) western blot analysis of LA-ET; Lane 1,
culture supernatant of LA. Lane 2, culture supernatant of LA-ET.
times with PBS (pH 7.4) and fixed in 4% paraformaldehyde in
PBS (pH 7.0) for 10 min. Following a 30 s wash in PBS, cells
were permeabilized in 0.5% Triton X-100 in PBS for 5 min. The
cells were washed once and then 200 µl of 100 nM rhodamine
phalloidin (Cytoskeleton, USA) was added and incubated in the
dark for 30 min. The cells were washed three times and the DNA
was counterstained for 30 s with 200 µl of 100 nM DAPI in
PBS. The samples were examined with a confocal laser scanning
microscope.
Oral Immunization of Mice with
Recombinant L. acidophilus Strains
Specific pathogen-free 6-week-old female BALB/c mice were
obtained from the Southern Medical University Laboratory
Animal Center (Guangzhou, China). All experimental and
animal handling procedures were approved by the Institution
Animal Care Committee of Southern Medical University (permit
no. 44002100006397) and were performed in accordance with
the approved relevant guidelines. The mice were sacrificed by
cervical dislocation at the end of the experiment. LA-ET strains
were grown as described above, then collected and washed twice
with sterile PBS. Mice were randomly divided into the following
three groups (n = 15): PBS, LA and LA-ET. The PBS group
was orally administered with 100 µl sterile PBS; the LA group
was orally administered with 1 × 109 CFU LA; and the LA-ET
group was orally administered with 1 × 109 CFU LA-ET. All
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mice were immunized on days 0, 3, 7, 10, 21, and 24 (the day
of first immunization regarded as 0 day) and serum samples were
collected on days 0, 7, 21, and 35 and stored at −80◦C until use.
Fecal extracts were collected on day 35 for sIgA measurement
by enzyme-linked immunosorbent assay (ELISA) as previously
described (Amani et al., 2010).
Determination of Antibody and Cytokine
Levels by ELISA
Total serum IgG (total IgG) and fecal IgA were measured by
indirect ELISA as previously described (Gao et al., 2009). ELISA
plates were coated with 100 µl of 10 µg/ml purified espA-
Tir-M protein (our laboratory stock). Serum and fecal extracts
were prepared as described above and diluted 1:50 and 1:10,
respectively. In addition, 5 µl serum (collected on day 34) was
assayed for murine interferon (IFN)-γ and interleukin (IL)-4
and IL-10 by quantitative ELISA using a mouse ELISA kit
(Elabscience, Hubei, China) according to the manufacturer’s
instructions. ELISA results were obtained by measuring the
OD450 using an EL9800 ELISA microplate reader (BioTek,
Winooski, VT, USA).
Survival Analysis of Immunized Mice
At 10 days after the last immunization, mice in each group were
randomly divided into two subgroups, of which one subgroup
(n = 10) received streptomycin (5 g/l) in the drinking water
from 3 days before infection until the end of the experiment to
clear intestinal flora and to enhance EHEC O157:H7 colonization
(Wadolkowski et al., 1990), whereas the other subgroup (n = 5)
was not treated with streptomycin. Mice were challenged by oral
inoculation of 1 × 1010 CFU of EHEC O157:H7 in PBS. Fecal
shedding of EHEC O157:H7 was monitored at 2-day intervals
as previously described (Amani et al., 2010). The number of
surviving mice in each group was recorded daily. All remaining
mice were sacrificed on day 15 post-challenge.
Histopathology
Mouse tissues were fixed by immersion in 10% neutral formalin,
embedded in paraffin, and cut into sections that were stained with
hematoxylin and eosin and was further microscopically evaluated
by two expert pathologists who were blinded to the experimental
groups.
Statistical Analysis
Statistical analysis was performed using SPSS v.21.0 software.
Differences in antibody and cytokine levels were evaluated by
one-way analysis of variance with the least significant difference
test. The duration of fecal shedding among groups were evaluated
by one-factor repeated measures ANOVA analysis. The number
of adherent bacteria was analyzed using Student’s t-test. P < 0.05
was considered statistically significant.
RESULTS
LA-ET Expressing espA-Tir-M Fusion
Protein in the Culture Supernatant
The espA-Tir-M fusion gene was amplified by overlap extension
PCR, yielding the expected 816-bp product, which was
visualized by agarose gel electrophoresis (data not shown).
The fragment was cloned into the pMG36e vector, and the
recombinant pMG36e-espA-Tir-M plasmid was transformed
into L. acidophilus cells. The supernatant proteins, LA-ET or LA
were analyzed by SDS-PAGE and western blotting. A 36-kDa
band was observed in the culture supernatant of the LA-ET lysate
but not in the supernatant of the LA lysate (Figure 1A), which
indicates that the LA-ET-expressed espA-Tir-M fusion protein
FIGURE 2 | Flow cytometry to determine the cytotoxicity of LA-ET. (A) Normal LoVo cells as control; (B) LoVo cells incubated with LA; (C) LoVo cells
incubated with LA-ET.
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was mainly a secreted protein. The secretion of espA-Tir-M was
confirmed by reaction with the anti-EHEC O157:H7 polyclonal
antibody with western blotting (Figure 1B).
LA-ET Was Safe in a Cell Model
Comparisons of the cytotoxic effect in LoVo cells showed no
obvious difference in the LA-ET group compared to the normal
group and LA group (Figure 2).
Inhibition of EHEC O157:H7 Colonization
and A/E Lesion Formation in LoVo Cells
The ability of LA-ET to interfere with EHEC O157:H7 adhesion
to LoVo intestinal epithelial cells was investigated using exclusion
and competition assays. For the former, both LA-ET and LA
excluded EHEC O157 from LoVo cells at a rate of almost
94% (P = 0.000). For the latter, the relative adhesion was
35.8%± 6.83% for LA-ET and 39.4%± 8.26% for LA (P= 0.501),
FIGURE 3 | Inhibition of EHEC O157:H7 colonization and A/E lesion
formation in LoVo cells. (A) Exclusion and competition adhesion inhibition
assays in LoVo cells. Results are expressed as relative adhesion relative to the
control without LA or LA-et. Data are shown as a percentage ± SD (n = 9).
∗∗P < 0.001 (one-way analysis of variance with least significant difference
test). (B) FAS detected A/E lesion formation. (a) Normal LoVo cell; (b) LoVo
cells were incubated with EHEC O157:H7 (MOI = 100:1) for 3 h; White arrows
show the A/E lesion and green arrows show EHEC O157:H7; (c) LoVo cells
were incubated with LA-ET (MOI = 500:1) for 3 h; (d) LoVo cells were
pre-incubated with LA-ET (MOI = 500:1) for 3 h and then EHEC O157:H7
(MOI = 100:1) was added for co-incubation for 3 h.
and both LA-ET and LA excluded EHEC O157 from LoVo cells
by about 60% (P = 0.000) (Figure 3A).
Fluorescent-labeled phalloidin staining of F-actin in LoVo
intestinal epithelial cells showed that EHEC O157:H7 challenge
of LoVo cells induced bacterial attachment to cells (green
arrows), effaced microvilli, and recruited F-actin into pedestals
to form A/E lesions (white arrows) (Figure 3Bb). By contrast,
cells pretreated with the LA-ET no longer demonstrated EHEC
O157:H7 adhesion and A/E lesions (Figure 3Bd). The LoVo cells
(Figure 3Ba) and LoVo cells incubated with LA-ET (Figure 3Bc)
were normal.
Serum IgG and Fecal sIgA Levels
Significant IgG responses were elicited in mice immunized with
LA-ET as compared to controls (Figure 4A). In addition, serum
antibody titer increased after each immunization with LA-ET
(0.24 ± 0.09 on day 7, 0.35 ± 0.10 on day 21, and 0.68 ± 0.14
on day 35), reaching a peak on day 35 (P = 0.000). sIgA was
also measured in fecal samples (Figure 4B). Consistent with
systemic antibody responses, sIgA levels were increased in mice
immunized with LA-ET (0.26 ± 0.08) as compared to control
mice (P = 0.000).
IL-4, IL-10, and IFN-γ Levels in
Immunized Mice
Cytokines play an important role as part of the immune
response against infections. Serum IL-4 concentrations were
significantly higher in the LA-ET group (285.2 ± 110.3 vs.
PBS, P = 0.000; vs. LA, P = 0.000) (Figure 5A). Serum IL-10
level was higher in the LA-ET (276.4 ± 138.1, P = 0.000) and
LA (127.8 ± 31.1; P = 0.048) groups than in the PBS group
(51.4 ± 19.5) (Figure 5B). Moreover, the serum IFN-γ level was
higher in the LA-ET group (102.2± 63.0) than in the control LA
(34.0± 20.9, P= 0.001) and PBS (31.9± 16.0, P= 0.000) groups
(Figure 5C).
Immunization with LA-ET Protects Mice
against EHEC O157:H7 Colonization
The protection efficiency of LA-ET was evaluated based
on survival, fecal shedding, and histopathology. Within the
streptomycin-treated immunization groups, 90% of mice were
susceptible to EHEC O157:H7 challenge and died between days
1 and 3 post-infection in the PBS control group (Figure 6A),
whereas 60% of mice in the LA group died between days 1 and
5. Clinical symptoms included weight loss, hunched posture and
lumbering gait. The post-infection survival data revealed that the
protection rate was 80% in LA-ET.
In addition, the duration of fecal shedding shown by the
LA-ET group was significantly shorter than that in the LA group
(P = 0.000); one vaccinated mouse had stopped shedding on day
9, and all mice were negative by day 13. In contrast, control mice
shed bacteria throughout the 15-day time course (Figure 6B).
No mice died in the non-streptomycin-treated immunization
groups when challenged with EHEC O157:H7. Comparisons
of the durations of EHEC O157:H7 fecal shedding showed
a significantly shorter duration in the LA-ET group
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FIGURE 4 | Detection of specific IgG in serum and sIgA in fecal samples. Antibody levels were determined by ELISA. The fusion protein espA-Tir-M was used
as a coating antigen. Horseradish peroxidase-labeled anti-mouse IgG or IgA was used as the test antibody. (A) Serum IgG levels were determined 0, 7, 21, and
35 days after the first immunization. (B) sIgA antibody in fecal samples collected on day 35 after the first immunization. Data are shown as the mean ± SD (n = 15).
∗P < 0.05, ∗∗P < 0.001 (one-way analysis of variance with least significant difference test).
FIGURE 5 | Serum levels of IL-4, IL-10, and IFN-γ. Cytokines were detected in serum collected 35 days after the first immunization. (A) The serum level of IL-4.
(B) The serum level of IL-10. (C) The serum level of IFN-γ. Data are reported as the mean ± SD (n = 10). ∗P < 0.05, ∗∗P < 0.001 (one-way analysis of variance with
least significant difference test).
FIGURE 6 | Survival analysis of immunized mice. (A) Protection rates in EHEC O157:H7-challenged mice. The number of mice that died was monitored for
15 days post-infection. (B,C) Changes in fecal shedding of EHEC O157:H7 in mice. Mice (n = 10) were orally challenged with 1010 CFU EHEC O157:H7 either under
oral streptomycin treatment condition (n = 10) (B) or without streptomycin treatment (n = 5) (C) after the last immunization and fecal shedding was monitored for
15 days. The limit of detection for plating was 100 CFU/100 mg feces. Data represent the mean ± SD. Data points in rectangles indicate a significant difference
between groups. ∗∗P < 0.001 (one-factor repeated measures ANOVA analysis).
(8.2 ± 0.89 days) compared to the LA and PBS groups
(11.4 ± 0.89 and 13.4 ± 0.89 days, respectively) (P = 0.000).
Additionally, the shorter duration of fecal shedding shown by
the LA group in comparison to the PBS group was significant
(P = 0.007) (Figure 6C).
Histopathological Findings
The intestine was dissected out from the mice sacrificed 15 days
after challenge. The pathological changes of non-immunized
infected mice included major intestinal injury (epithelial cell
necrosis) accompanied by damage to the kidney (hyperemia of
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FIGURE 7 | Histopathological analysis of the colon of immunized mice challenged with EHEC O157:H7. Tissue was obtained from mice sacrificed 15 days
after infection. Sections of paraffin-embedded tissue were stained with hematoxylin and eosin and examined by light microscopy. (A) Normal mice; (B) PBS group;
(C) LA group; and (D) mice immunized with LA-ET group.
mesenchyme capillaries), liver (mesenchyme hyperemia), and
spleen (splenic sinusoid dilation and ecchymosis) (data not
shown). However, the colon of immunized mice infected with
EHEC O157:H7 appeared normal, and these animals produced
well-formed stools with no obvious mucosal thickening, similar
to non-infected mice (Figure 7).
DISCUSSION
Enterohemorrhagic Escherichia coli O157:H7 is a major cause of
gastroenteritis. Most infected individuals develop HUS, which
is prevalent in children (Pennington, 2010). EHEC O157:H7
adheres to host epithelial cells as the first step of the infection
process, leading to pedestal formation and effacement of
microvilli, which characterize the A/E lesions. Hence, inhibiting
pathogen adhesion to epithelial cells may prevent colonization
and limit opportunistic infection (Johnson-Henry et al., 2007).
It has been suggested that probiotics are effective in preventing
adhesion and invasion of enteric pathogens (Dini et al., 2016).
Probiotics may reduce intestinal infections by competing with
pathogens for binding sites on the intestinal wall as well as
for nutrients, and also by producing antibacterial compounds
and lactic acid, or via immunomodulation (Roselli et al., 2006;
Delcenserie et al., 2008; Amara and Shibl, 2015).
In this study, LA and LA-ET were both shown to exclude
EHEC O157 from LoVo cells in exclusion and competition
assays, which highlights the important role of probiotics in
interrupting progressive infection with EHEC O157:H7. This
finding was consistent with studies in which probiotics reduced
intestinal infection (Resta-Lenert and Barrett, 2003; Rodrigues
et al., 2012). Furthermore, the FAS test showed that LA-ET has
the ability to inhibit A/E lesions. It is obvious that LA-ET inhibits
EHEC O157:H7 to induce the formation of A/E lesions and
adhesion to cells. However, recombinant anti-EspA antibodies
block EHEC O157:H7-induced A/E lesions in vitro but do
not affect EHEC O157:H7 adhesion to host cells (La Ragione
et al., 2006). Therefore, the effect of LA-ET in excluding EHEC
O157:H7 from adhering to LoVo cells may be attributed to the
probiotics competing with pathogens for binding sites.
LA-ET used for oral immunization can prevent gastric
infection and allows direct contact between the antigen and the
immune system. Significant IgG and sIgA responses were elicited
in mice immunized with LA-ET and protective effects were
also confirmed. A previous study showed that attenuated EIS-
producing recombinant Salmonella induced significant specific
IgG in serum and sIgA in feces to protect mice from a challenge
of EHEC O157:H7 (Gu et al., 2011). These findings indicate that
antibody-mediated immunity participates in the prevention of
EHEC O157:H7 infection. In addition, the rate of protection was
consistent with antibody and cytokine levels in vaccinated mice.
LAB strains for vaccines can be specifically selected according
to their function to modulate dendritic cells and induce Th1,
Th2, or mixed Th1/Th2 responses (Wells, 2011). The major
cytokines associated with Th1 cells are IL-2, TNF-α and IFN-γ,
which can enhance T cell cytotoxicity and immune responses.
Th2 cells secrete IL-4, IL-5, and IL-10, which mainly promote
antibody production and mediate humoral immune responses
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(Zhu et al., 2016). We observed that LA-ET enhanced the
production of IFN-γ, IL-4, and IL-10, indicating that a mixed
Th1/Th2 response was induced. Thus, immunizing mice with
LA-ET induced humoral and cellular immunity, consistent with
previous findings (Ahmed et al., 2014).
Reduced intestinal colonization is regarded as an important
criterion for protection against EHEC O157:H7 infection. Oral
immunization of mice with LA-ET resulted in a reduction of
EHEC O157:H7 fecal shedding in two infection models. The
infection model under the oral streptomycin treatment condition
emphasized the protective effects of humoral and cellular
immune responses induced by LA-ET. LA-ET blocks adhesion of
EHEC O157:H7 to intestinal tract, which may be associated with
the sIgA. The sIgA antibodies play an important role in blocking
the attachment of EHEC O157:H7 to epithelial cells (Ghaem-
Maghami et al., 2001). The infection model without streptomycin
treatment took into account the probiotic properties of LA-
ET. Probiotics have been shown to protect mice against EHEC
O157:H7 (Shu and Gill, 2002). In this study, we found that LA
elevated IL-10 secretion, reduced EHEC O157:H7 colonization
(without streptomycin treatment), and increased the survival rate
in mice, suggesting that L. acidophilus strains play an important
role in protecting mice against EHEC O157 infection and may
be useful vaccine carriers for combating enteric pathogens in
humans.
The histopathology indicates that administration of LA-ET
has the ability to reduce or inhibit A/E lesions, which suggests
that LA-ET could reduce the colonization of EHEC O157:H7
in the intestinal tract and inhibit A/E lesions. Moreover, the
mechanism utilized by LA-ET against EHEC O157:H7 is different
from that of antibiotics. LA-ET was safe in a cell model, but
EHEC O157:H7 released toxins when treated with antibiotics,
which could cause toxin-induced systemic injury. Thus, LA-ET is
a promising candidate vaccine against EHEC O157:H7, especially
for children and the elderly. Although oral immunization with
LA-ET induced protective immunity, an important deficiency
should be noted. First, the antigen dose provided by LA-
ET in vivo cannot be measured. In addition, the expression
level of the antigen in LAB is weak and the enzymes in the
gastrointestinal tract may digest the proteins (Guo et al., 2015),
which may reduce the effects of antigen. Furthermore, Ahmed
et al. (2013) previously constructed a recombinant L. lactis strain
expressing the EHEC antigen EspB and this strain expressed
rather low levels of antigen EspB. However, they optimized
the expression of EspB in L. lactis through secretion of EspB
either under constitutive or nisin-inducible control, and the
strains successfully induced immune responses (Ahmed et al.,
2014). Collectively, we speculated that an oral vaccine would be
more effective, than LAB vaccines that are engineered to co-
express antigens with cytokines or made inducible in different
mutants, or new strains that are selected to have enhanced
adjuvant or targeting capacities (Rosales-Mendoza et al., 2016).
In our study, the antigen expressed by LA-ET was not strong,
which was shown by SDS-PAGE analysis. This is the first report
of the use of L. acidophilus expressing the EHEC O157:H7
antigen. Thus, the optimal condition for LA-ET that can enhance
stimulation of strong immune responses still needs to be
explored. High expression of L. lactis vector is promising for
vaccine development.
CONCLUSION
LA-ET was capable of inhibiting A/E lesions and bacterial
adhesion in vitro, and oral immunization strain induced both
humoral and cellular immune responses in vivo and protected
against EHEC O157:H7 colonization and infection in mice. These
findings suggest that oral LA-ET is a promising candidate vaccine
against EHEC O157:H7 infection.
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